DALLAS, October 13, 2014 /PRNewswire/ --
The EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023 is a 30 pages market research published in October 2014. Allergic conjunctivitis could be categorized as seasonal allergic conjunctivitis (SAC), which is the most common one, perennial allergic conjunctivitis (PAC), giant papillary conjunctivitis (GPC), vernal keratoconjunctivitis (VKC), and atopic keratoconjunctivitis (AKC) (Calonge, 1999). SAC and PAC represent the majority of diagnoses; whereas, AKC, VKC and GPC are relatively rare (Ono and Abelson, 2005). Complete report is available at http://www.marketoptimizer.org/epicast-report-allergic-conjunctivitis-epidemiology-forecast-to-2023.html .
Allergic conjunctivitis condition is more prevalent in warm climatic conditions and among Afro-Caribbeans, Arabs, and Asians and less frequent among the White populations. Older population-based studies estimated allergic conjunctivitis prevalence of 15-20%; however, more recent studies show allergic conjunctivitis prevalence as high as 40% in adults ages 15 years and older (Bogacka, 2003; Singh et al., 2010). Furthermore, research suggests that allergic conjunctivitis is often under-diagnosed and consequently under-treated except when it is severe.
This EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023 provides an overview of the risk factors, comorbidities, and global and historical trends for allergic conjunctivitis in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the total one-year prevalent cases of allergic conjunctivitis segmented by sex and age (0-14 years, 15-34 years, 35-54 years, 55-74 years, and =75 years) in these markets. Order a copy of this research at http://www.marketoptimizer.org/contacts/purchase?rname=11450 .
The epidemiologists forecast that the total prevalent cases of allergic conjunctivitis in the 6MM will grow by 5.40% over the next decade, from 155,455,174 total prevalent cases in 2013 to 163,925,356 total prevalent cases in 2023, with almost 50% of the total prevalent cases occurring in the US alone. The increase in the number of total prevalent cases of allergic conjunctivitis in the 6MM can be attributed to changing population demographics in the respective markets. However, further epidemiological research is warranted given that there is a paucity of national and international data evaluating the prevalence of allergic conjunctivitis worldwide. There is also a need to clearly demarcate the allergic conjunctivitis population from the overall allergy population, as currently available epidemiological literature suggests a significant overlap in allergy prevalence with other diseases, such as rhinoconjunctivitis.
Reasons to buy EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023 include: Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market. Quantify patient populations in the global allergic conjunctivitis market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for allergic conjunctivitis therapeutics in each of the markets covered.
List of Tables provided in this research cover:
Table 1: Risk Factors and Comorbidities for Allergic Conjunctivitis 10
Table 2: 6MM, Sources of Allergic Conjunctivitis Prevalence Data Used in the Epidemiology Forecast 12
Table 3: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, All Ages, Both Sexes, N, 2013-2023 16
Table 4: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Age, Both Sexes, N (Row %), 2013 17
Table 5: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Sex, All Ages, N (Row %), 2013 19
1.2 List of Figures
Figure 1: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, All Ages, Both Sexes, N, 2013-2023 16
Figure 2: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Age, Both Sexes, N, 2013-2023 18
Figure 3: 6MM, Total Prevalent Cases of Allergic Conjunctivitis, by Sex, All Ages, N, 2013 20
Another research titled CF101 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022 provides overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. It also offers detailed information on CF-101 including product description, safety and efficacy profiles as well as a SWOT analysis; Sales forecast for CF-101 for the top two countries from 2012 to 2022 as well as Sales information covered for Japan and China. Read more at http://www.marketoptimizer.org/cf101-dry-eye-syndrome-forecast-and-market-analysis-to-2022.html .
On similar lines, we have Diquas (Dry Eye Syndrome) - Forecast and Market Analysis to 2022 research report that says Diquas ophthalmic solution 3%, developed by Santen Pharmaceutical, is the first approved P2Y2 receptor agonist to be formulated as an ophthalmic solution for the treatment of DES. It improves dry eye symptoms by promoting the secretion of natural tear elements - mucin, lipids, and water - to significantly improve tear production. Obtain sales forecast for Diquas from 2012-2022 in top two countries (Japan and China), Understand and capitalize by identifying products that are most likely to ensure a robust return, Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential and more through the research available at http://www.marketoptimizer.org/diquas-dry-eye-syndrome-forecast-and-market-analysis-to-2022.html .
MarketOptimizer.org is a database of selected syndicated market reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE Market Optimizer